Results 21 to 30 of about 27,235 (300)
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Antibodies, 2013 Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials.
Luis Alvarez-Vallina +3 more
doaj +1 more source
Cell Discovery, 2022 The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs).
Yingdan Wang +17 more
doaj +1 more source
mAbs, 2021 Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging.
Pallavi Bhatta +12 more
doaj +1 more source
Emerging Antibodies in Cancer Therapy
Advanced NanoBiomed Research, 2023 Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj +1 more source
Bispecific antibodies for cancer therapy [PDF]
Immunotherapy, 2009 Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors.
Patrick Chames, Daniel Baty
openalex +4 more sources
Nature Communications, 2022 Bispecific antibodies can have advantages compared to antibody cocktails. Here, the authors engineer and characterize two different approaches for generating bispecific SARS-CoV-2 specific antibodies and find that only one design increases antigen ...
Zhiqiang Ku +24 more
doaj +1 more source
Bispecific antibodies in cancer immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2016 Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Zhong Wang, Qing Li, Siqi Chen, Jing Li
openaire +2 more sources
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Frontiers in Immunology, 2022 Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically revolutionized the therapeutic strategy against advanced malignancies, inspiring the exploration of various types of therapeutic antibodies.
Jing Wei +3 more
doaj +1 more source
Bispecific antibodies in cancer immunotherapy [PDF]
Current Opinion in Biotechnology, 2020 Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire +3 more sources
Producing and prospects for the use of bispecific antibodies for the treatment of cancer
Успехи молекулярной онкологии, 2019 Bispecific antibody molecules contain two different antigen-binding centers. Particular interest in bispecific antibodies is due to their therapeutic application.
S. E. Sedykh, G. A. Nevinsky
doaj +1 more source